OSI-211, a novel liposomal topoisomerase I inhibitor, is active in SCID mouse models of human AML and ALL. (Q44512464)

3 December 2017

title

OSI-211, a novel liposomal topoisomerase I inhibitor, is active in SCID mouse models of human AML and ALL. (English)

1 reference

3 December 2017

Blake Tomkinson

1

1 reference

3 December 2017

Ray Bendele

2

1 reference

3 December 2017

Francis J Giles

3

1 reference

3 December 2017

Eric Brown

4

1 reference

3 December 2017

Atherton Gray

5

1 reference

3 December 2017

Karen Hart

6

1 reference

3 December 2017

Jeremy D LeRay

7

1 reference

3 December 2017

Denny Meyer

8

1 reference

3 December 2017

Michelle Pelanne

9

1 reference

3 December 2017

David L Emerson

10

1 reference

3 December 2017

publication date

1 November 2003

1 reference

3 December 2017

1 reference

3 December 2017

volume

27

1 reference

3 December 2017

issue

11

1 reference

3 December 2017

page(s)

1039-1050

1 reference

Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900092-4

7 January 2021

Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900092-4

7 January 2021

Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900092-4

7 January 2021

Acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900092-4

7 January 2021

Pre-clinical evaluation of SN-38 and novel camptothecin analogs against human chronic B-cell lymphocytic leukemia lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900092-4

7 January 2021

Activity of oral and intravenous 9-aminocamptothecin in SCID mice engrafted with human leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900092-4

7 January 2021

Water soluble inhibitors of topoisomerase I: quaternary salt derivatives of camptothecin

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900092-4

7 January 2021

Synthesis and antitumor activity of novel water soluble derivatives of camptothecin as specific inhibitors of topoisomerase I

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900092-4

7 January 2021

Liposomal lurtotecan (NX211): determination of total drug levels in human plasma and urine by reversed-phase high-performance liquid chromatography.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900092-4

7 January 2021

Analysis of enzymatically amplified β-globin and HLA-DQα DNA with allele-specific oligonucleotide probes

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900092-4

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900092-4

7 January 2021

Design and analysis of trials of salvage therapy in acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900092-4

7 January 2021

Evaluation of monoclonal antibody-mediated anti-acute myeloid leukemia immunotherapy in a SCID/hu model

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900092-4

7 January 2021

Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900092-4

7 January 2021

Biodistribution of NX211, liposomal lurtotecan, in tumor-bearing mice

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900092-4

7 January 2021

Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900092-4

7 January 2021

Marked interspecies variations concerning the interactions of camptothecin with serum albumins: a frequency-domain fluorescence spectroscopic study

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900092-4

7 January 2021

Topotecan in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900092-4

7 January 2021

A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900092-4

7 January 2021

Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900092-4

7 January 2021

Phase II trial of topotecan as a 21-day continuous infusion in patients with advanced or metastatic adenocarcinoma of the pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900092-4

7 January 2021

Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900092-4

7 January 2021

Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900092-4

7 January 2021

Continuous infusional topotecan in advanced breast and non-small-cell lung cancer: no evidence of increased efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900092-4

7 January 2021

Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900092-4

7 January 2021

Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900092-4

7 January 2021

Topoisomerase I inhibition by the camptothecin analog Gl147211C. From the laboratory to the clinic

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900092-4

7 January 2021

A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900092-4

7 January 2021

Phase I/pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900092-4

7 January 2021

10.1016/S0145-2126(03)00092-4

Identifiers

DOI

1 reference

3 December 2017

1 reference